ClinicalTrials HQ

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)

Recruiting · NCT05949125 · Registry updated 2026-09-24
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 12026-09-24NCT05949125

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Allucent (NL) BV1
AvenCell Europe GmbH3

15 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Amsterdam University Medical CenterAmsterdamNetherlands1
Charité Universitätsmedizin BerlinBerlinGermany4
Erasmus University Medical CenterRotterdamNetherlands1
Klinikum der Universität MünchenMunichGermany2
Medizinische Hochschule HannoverHanoverGermany42
University Medical Center Groningen (UMCG)GroningenNetherlands1
Universitätsklinikum DresdenDresdenGermany5
Universitätsklinikum EssenEssenGermany39
Universitätsklinikum FrankfurtFrankfurtGermany29
Universitätsklinikum Hamburg-EppendorfHamburgGermany29
Universitätsklinikum HeidelbergHeidelbergGermany47
Universitätsklinikum KölnCologneGermany15
Universitätsklinikum MarburgMarburgGermany2
Universitätsklinikum UlmUlmGermany17
Universitätsklinikum WürzburgWürzburgGermany22